In the U.S., nearly half-million fatalities is associated with sudden cardiac death each year. Physiologically, sudden cardiac death is malfunction in the electrical system of the heart.
In fact, among young athletes, a leading cause of sudden cardiac death is arrhythmogenic cardiomyopathy (ACM). ACM is a genetic disease wherein the healthy heart muscle is taken over by scar tissue and fat in a period of time.
Meanwhile, a researcher at the College of Medicine, Florida State University undertook a research initiative and has developed a better understanding of the pathological characteristics of ACM. In addition, the researcher has developed promising avenues for prevention of the disease.
Clinically, individuals with ACM carry mutation causing arrhythmias. In the normal course, arrhythmias are non-fatal if managed and treated properly. However, the research undertaken by the researcher reveals some significant facts. It shows that exercise amplifies arrhythmias and also causes extensive death. To prevent this, the only option is to avoid participation in exercise –an awful irony for a healthy and worthwhile endeavor.
As such, endurance exercise particularly leads to large-scale myocyte cell death, reveals the study. This happens due to mitochondrial dysfunction in individuals who suffer from ACM – an inherited heart disease.
Anatomically, several thousand mitochondria are present in nearly in each cell in the body. Called ‘powerhouse’ of cells, mitochondria process oxygen and converts food into energy. Mitochondria produce 90 percent energy in the body to function properly. Besides this, mitochondria also plays an important role as protective antioxidants.
In the event of mitochondria fails to function properly, and myocyte in the heart dies, healthy muscles are replaced by fatty cells and scar tissue.
The global rise in the elderly population, along with the preference of pain management devices over pain killer pharmaceutical drugs, in anticipated to fuel the growth of the pain management devices market. The increasing prevalence of chronic pain problems in adults is a key driver shaping technological developments in the pain management market. Majority of pain management devices have applications in healthcare sectors such as cardiac rhythm management, oncology, cosmetology, and gynecology.
Oncology sector is a rapidly emerging segment in pain management devices market. The increasing prevalence of severe neuropathic pain in some of the developed countries is also seen to bolster the growth in the market.
Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7080
The growing number of FDA-approved pain management devices used for treating the chronic pains arising from conditions such as fibromyalgia, diabetic neuropathy, and sciatica is anticipated to increase the revenue of global pain management devices market.
Key players keen on launching FDA-approved devices
Aspiring players in the field of pain management devices market are seen engaging in research and development for the treatment of chronic pain diseases such as cancer. Specialized research in the neurobiology of the cancer pain paves the way for innovation. Players and the manufacturers of medical devices to design pain management devices by understanding unique characteristics of pain in various cancer patients, such as cancer induced bone pain (CIBP).
Some of the major players in the pain management devices market are Boston scientific Corp., Stryker Corporation, Medtronic Plc., Colfax Corp, and Omron healthcare Inc.
Regionally, North America region is leading in revenue generation in the global pain management devices market due to the early uptake of cutting-edge pain management devices. Presence of the advanced infrastructure for medical care has made U.S. a very lucrative market for pain management devices.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7080
Biopsies have played a huge role in the advancement of the molecular medicine sector. Technological developments in molecular medicine have significantly improved the molecular classification of cancers and has paved the way for growth in the cancer biopsy market.
Emerging technologies in the field such as fine needle aspiration biopsies are being incorporated in the diagnosis of various types of cancers such as thyroid cancer, colorectal cancer, breast cancer, blood cancer, and lung cancer. The growing trend of image-guided needle biopsies is anticipated to spur the growth in cancer biopsies market owing to their role in precision medicine field.
Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7079
Liquid biopsy of cancer is another emerging diagnostic test that has the potential to shape the market. It is a minimally invasive process of extraction of the circulating tumor cells (CTCs). However, liquid biopsy poses technical challenges for radiologists who deal with the isolation of CTCs. Advancements in the next-generation sequencing techniques could potentially amplify the growth of the cancer biopsy market.
Bioinformatics players increasing investments in the cancer biopsy market
A growing number of multidimensional research on the new techniques for biopsies and molecular medicine in projected to expand the avenue for aspiring players in the cancer biopsy market. Besides this, players that pioneered in bioinformatics are seen to increase their investments and research initiative to benefit the cancer biopsy market. They are launching advanced data analysis platforms that will help the clinicians and patients in the field of oncology. Some of the key players in the cancer biopsy market include Guardant Health, Myriad Genetics, Chronix Biomedical, Hoffman-La Roche Ltd., and Thermo Fisher Scientific Inc.
Regionally, North America has been offering incredible growth opportunities for the stakeholders and industry players in the cancer biopsy market. A large share of revenue in the market in the last few years was generated in the U.S. Advancements in precision medicine in oncology has contributed to growth in the market. Prevalence of breast cancer and growing awareness of impact of cancer on patients and their families is seen to indirectly spur the growth of cancer biopsy market in Asia Pacific region.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7079
Diabetes can cause various visual impairments in patients such as glaucoma, double vision, cataract, retinopathy, and diabetic macular edema. Increasing number of diabetic patients with potential visual impairments has spurred the growth of the global ophthalmic refractometer market. Ophthalmic refractometer is a device used for measuring the strength and power of the lenses to provide vision disorder patients with suitable eyeglasses.
The number of visual problems arising from lifestyle conditions such as stress, improper nutrition, unhealthy lifestyle, underlying diseases is high. According to WHO, 1 billion people over the globe have visual impairment problems that could have been prevented or have yet to be addressed. The growing number of population with diabetes and comorbid visual impairments is one of the key drivers for growth in the market.
Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7077
On the other hand, high cost of equipment, i.e. ophthalmic refractometer, can prove to be a barrier for aspiring players from entering the global market. The cost of a single ophthalmic refractometer is high. Therefore, it cannot be easily acquired by small and medium scale hospitals. The high initial funding and the technological skillset required for the operation might be a hindrance for the growth of ophthalmic refractometer market.
North America dominates the ophthalmic refractometer market
Regionally, North America is the region that dominates the global ophthalmic refractometer market. It is expected that the opportunities in the region will continue to grow steadily in the market during the forecast period, owing to the increasing prevalence of age-related macular degeneration among the resident population. Asia Pacific region is expected to witness substantial growth in the ophthalmic refractometer market. One of the major factors driving this growth is increased expenditure on the healthcare infrastructure by the emerging countries in the region.
Global ophthalmic refractometer market witnesses high competition among players. Players in the market are engaging in constant research and development to stay ahead of their competitors. Some of the key players in the global ophthalmic refractometer market are NIDEK Co. Ltd., Eye Care Leader LLC, Canon Inc., Carl Zeiss AG, and Birmingham Optical Group Ltd.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7077